Bolt Biotherapeutics, Inc.
BOLT evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BOLT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and immuno-oncology therapies, with no approved products and a history of operating losses.
Key risk: Going concern uncertainty
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 6 clinical trials for Bolt Biotherapeutics, Inc..
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and immuno-oncology therapies, with no approved products and a history of operating losses.
- Bolt Biotherapeutics has not generated any product revenue and has incurred significant operating losses since inception in 2015, with a net loss of $7.7M for the quarter ended June 30, 2026 [sec].
- As of June 30, 2026, the company held cash and equivalents of $14.6M and shareholders' equity of $38.8M [sec].
- The company's independent auditor has expressed substantial doubt about its ability to continue as a going concern, as of December 31, 2025 [sec_mda · as of 2026-03-12].
- Bolt's primary uses of cash include funding clinical trials, manufacturing product candidates, and research and development activities [sec_mda · as of 2026-05-12].
- The company has an accumulated deficit of $427.4M as of December 31, 2024 [sec_mda · as of 2025-03-24].
What works
- Bolt has a focused pipeline of ADC and immuno-oncology candidates targeting solid tumors, with ongoing clinical trials [sec_mda · as of 2026-05-12].
- The company has experience in managing clinical-stage programs and has achieved key milestones in its development plans [sec_mda · as of 2026-05-12].
- Bolt's technology platform may offer differentiated mechanisms of action in the ADC space, potentially addressing unmet medical needs [sec_mda · as of 2025-03-24].
What to weigh
- Bolt has no approved products and has never generated product revenue, relying entirely on external capital to fund operations [sec_mda · as of 2025-03-24].
- The company faces substantial doubt about its ability to continue as a going concern, with cash runway limited and a need for additional capital [sec_mda · as of 2026-03-12].
- Clinical trials are costly and uncertain, and Bolt's funding requirements are expected to grow as programs advance, increasing financial risk [sec_mda · as of 2026-05-12].
- The company has a history of significant operating losses, with an accumulated deficit of $427.4M as of December 31, 2024 [sec_mda · as of 2025-03-24].
From the filings
Quoted directly from source documents.
The company has not generated any product revenue and has incurred significant operating losses.
“Since inception in 2015, we have not generated any product revenue and have incurred significant operating losses.”
SEC MD&A · March 24, 2025
There is substantial doubt about the company's ability to continue as a going concern.
“independent registered public accounting firm included an explanatory paragraph in its report on our financial statements as of, and for the year ended, December 31, 2025, describing the existence of substantial doubt about our ability to continue as a going concern.”
SEC MD&A · March 12, 2026
The company's accumulated deficit as of December 31, 2024 was $427.4 million.
“As of December 31, 2024, we had an accumulated deficit of $427.4 million.”
SEC MD&A · March 24, 2025
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Auditor expressed substantial doubt about ability to continue as a going concern as of Dec 31, 2025 [sec_mda · as of 2026-03-12].
- No product revenue — Company has never generated product revenue and relies on external capital [sec_mda · as of 2025-03-24].
- Limited cash runway — Cash of $14.6M as of June 30, 2026 may not be sufficient to fund operations beyond near term [sec].
- Clinical trial costs and uncertainty — Clinical trials are costly and timing of progress and expenses is uncertain [sec_mda · as of 2026-05-12].
What to watch
- Ability to raise additional capital through equity or partnerships to fund ongoing clinical programs [sec_mda · as of 2026-05-12].
- Progress and results of clinical trials for ADC and immuno-oncology candidates [sec_mda · as of 2026-05-12].
- Updates on cash position and runway, given the going concern warning [sec_mda · as of 2026-03-12].
- Any regulatory milestones or partnership announcements that could provide non-dilutive funding [sec_mda · as of 2025-11-12].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Bolt Biotherapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Bolt Biotherapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
8.9 months
D/E 2.19 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.4%
- Days to cover
- 0.3
- Shares short
- 6,999
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BOLT short interestGovernance
Frequently asked questions
What is the AI investment thesis for Bolt Biotherapeutics, Inc.?
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) and immuno-oncology therapies, with no approved products and a history of operating losses.
Who is the CEO of Bolt Biotherapeutics, Inc.?
Mr. William P. Quinn is the chief executive officer of Bolt Biotherapeutics, Inc. (BOLT).
Where is Bolt Biotherapeutics, Inc. headquartered?
Bolt Biotherapeutics, Inc. (BOLT) is headquartered in Redwood City, CA, United States.
What therapeutic areas does Bolt Biotherapeutics, Inc. focus on?
Bolt Biotherapeutics, Inc. develops therapies across Oncology, Cardiovascular, Nephrology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.